Robert Paul Hasserjian, M.D.
This page shows the publications co-authored by Robert Hasserjian and Valentina Nardi.
Bedside to Bench and Back: Identifying a New Clinically Relevant Driver in Pediatric Acute Myeloid Leukemia. Blood Cancer Discov. 2022 Feb 16.
Premalignant Clonal Hematopoietic Proliferations. Am J Clin Pathol. 2019 08 01; 152(3):347-358.
Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Surg Pathol Clin. 2016 Mar; 9(1):143-63.
Routine conventional karyotyping of lymphoma staging bone marrow samples does not contribute clinically relevant information. Am J Hematol. 2015 Jun; 90(6):529-33.
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol. 2012 Jul 01; 30(19):2340-7.
An unusual lymphoma involving the GI tract and bone marrow. Am J Hematol. 2022 Mar 07.
Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. Am J Hematol. 2021 11 01; 96(11):E420-E423.
JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology. Am J Surg Pathol. 2021 07 01; 45(7):895-904.
Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Hum Pathol. 2019 04; 86:1-11.
Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Mol Diagn. 2015 Nov; 17(6):661-8.
High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol. 2015 Apr; 28(4):552-63.
TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes. Cancers (Basel). 2021 Nov 02; 13(21).
Myeloid/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol. 2021 09; 34(9):1673-1685.
Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma. Oncologist. 2021 07; 26(7):e1263-e1272.
Genomic alterations in patients with somatic loss of the Y chromosome as the sole cytogenetic finding in bone marrow cells. Haematologica. 2021 02 01; 106(2):555-564.
Pan-sarcoma genomic analysis of KMT2A rearrangements reveals distinct subtypes defined by YAP1-KMT2A-YAP1 and VIM-KMT2A fusions. Mod Pathol. 2020 11; 33(11):2307-2317.
Pan-Cancer Landscape Analysis Reveals Recurrent KMT2A-MAML2 Gene Fusion in Aggressive Histologic Subtypes of Thymoma. JCO Precis Oncol. 2020; 4.
Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group. Mod Pathol. 2019 09; 32(9):1373-1385.
Therapy-Related Erythroleukemia in a Man With Metastatic Ewing Sarcoma: A Clinical Role for Advanced Molecular Diagnostics. JCO Precis Oncol. 2018 Nov; 2:1-6.
High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825.
Combined Targeted Therapy for BRAF-Mutant, Treatment-Related Acute Myeloid Leukemia. JCO Precis Oncol. 2017 Nov; 1:1-7.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.